Peptoids with Antibiofilm Activity against the Gram Negative Obligate Anaerobe, <i>Fusobacterium nucleatum</i>
Jamie Toole,
Hannah L. Bolt,
John J. Marley,
Sheila Patrick,
Steven L. Cobb,
Fionnuala T. Lundy
Affiliations
Jamie Toole
Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
Hannah L. Bolt
Department of Chemistry, Biophysical Sciences Institute, Durham University, South Road, Durham DH1 3LE, UK
John J. Marley
Department of Oral Surgery, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK
Sheila Patrick
Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
Steven L. Cobb
Department of Chemistry, Biophysical Sciences Institute, Durham University, South Road, Durham DH1 3LE, UK
Fionnuala T. Lundy
Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
Peptoids (oligo N-substituted glycines) are peptide analogues, which can be designed to mimic host antimicrobial peptides, with the advantage that they are resistant to proteolytic degradation. Few studies on the antimicrobial efficacy of peptoids have focused on Gram negative anaerobic microbes associated with clinical infections, which are commonly recalcitrant to antibiotic treatment. We therefore studied the cytotoxicity and antibiofilm activity of a family of peptoids against the Gram negative obligate anaerobe Fusobacterium nucleatum, which is associated with infections in the oral cavity. Two peptoids, peptoid 4 (NaeNpheNphe)4 and peptoid 9 (NahNspeNspe)3 were shown to be efficacious against F. nucleatum biofilms at a concentration of 1 μM. At this concentration, peptoids 4 and 9 were not cytotoxic to human erythrocytes or primary human gingival fibroblast cells. Peptoids 4 and 9 therefore have merit as future therapeutics for the treatment of oral infections.